The overall goal of this research plan is to understand the significance of differences between human and mouse Toll-like receptor 9 (TLR9). Both the specificity of TLR9 and its expression among immune cells differ between these species, making it difficult to extend mouse studies of TLR9 function into humans. In this proposal, a human TLR9 transgenic cassette will be used to create mouse strains expressing human TLR9 or mouse TLR9 with the human expression pattern. The function of TLR9 in these mice will be evaluated using a number of criteria.

Public Health Relevance

There is considerable clinical interest in using synthetic ligands of Toll-like receptor 9 (TLR9) to treat infectious disease, generate better vaccines, and alleviate symptoms of allergy or asthma. Unfortunately, differences in the function of TLR9 in humans and mice have made it difficult to assess the efficacy of such approaches in animal models other than non-human primates. This proposal focuses on creating and characterizing """"""""humanized"""""""" TLR9 mice that will enable the comparison of TLR9 function between humans and mice.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21AI079358-01A2
Application #
7738989
Study Section
Immunity and Host Defense Study Section (IHD)
Program Officer
Palker, Thomas J
Project Start
2009-06-05
Project End
2011-05-31
Budget Start
2009-06-05
Budget End
2010-05-31
Support Year
1
Fiscal Year
2009
Total Cost
$182,814
Indirect Cost
Name
University of California Berkeley
Department
Biochemistry
Type
Schools of Arts and Sciences
DUNS #
124726725
City
Berkeley
State
CA
Country
United States
Zip Code
94704
Barbalat, Roman; Ewald, Sarah E; Mouchess, Maria L et al. (2011) Nucleic acid recognition by the innate immune system. Annu Rev Immunol 29:185-214
Barbalat, Roman; Lau, Laura; Locksley, Richard M et al. (2009) Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands. Nat Immunol 10:1200-7